Neutrophil-to-lymphocyte Ratio As a Predictive or Prognostic Factor for Gastric Cancer Treated with Nivolumab: a Multicenter Retrospective Study

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Oct 24

PMID 30349646

Citations 37

Authors

Takatsugu Ogata

Hironaga Satake

Misato Ogata

Yukimasa Hatachi

Kentaro Inoue

Madoka Hamada

Hisateru Yasui

Affiliations

Soon will be listed here.

Abstract

Introduction: The neutrophil-to-lymphocyte ratio (NLR) is effective as a predictive factor for lung cancer treated with nivolumab. The objective of this study was to determine the effectiveness of NLR for patients with advanced gastric cancer (AGC) treated with nivolumab.

Methods: This was a multicenter, retrospective study of patients with AGC treated with nivolumab from June 2017 to December 2017. The NLRs were calculated before the first cycle (NLR) and two weeks after the first administration (NLR).

Results: Twenty-six patients were enrolled (males 19, females 7) with a median age of 64 years. The overall response rate was 15%. The median PFS was 80 days (range, 11 - 265) and the median OS was 290 days (range, 21 - 332). Stratified with high NLR (≥5) and low NLR (<5), the median PFS was shorter in the high NLR arm (87 vs. 45 days; p=0.066) and significantly shorter in the high NLR arm (94 vs. 28 days; p=0.014). The median OS was significantly shorter in the high NLR arm (290 vs. 175 days; p=0.008) and in the high NLR arm (290 vs. 69 days; p<0.001).

Conclusion: NLR may be an effective prognostic factor in patients with AGC treated with nivolumab.

Citing Articles

Baseline (derived) neutrophil-lymphocyte ratio associated with survival in gastroesophageal junction or gastric cancer treated with ICIs.

Yu C, Jiang H, Wang L, Jiang Z, Jin C Front Oncol. 2025; 15:1404695.

PMID: 39926278 PMC: 11802431. DOI: 10.3389/fonc.2025.1404695.

Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis.

Su J, Li Y, Tan S, Cheng T, Luo Y, Zhang L Sci Rep. 2025; 15(1):446.

PMID: 39747391 PMC: 11695637. DOI: 10.1038/s41598-024-84890-3.

Neutrophil‑to‑lymphocyte ratio and risk of disease progression in patients with nivolumab‑treated unresectable or recurrent gastric cancer.

Hayashi H, Yasufuku I, Sato Y, Fujibayashi S, Chikaishi W, Endo M Oncol Lett. 2024; 29(1):20.

PMID: 39492934 PMC: 11526420. DOI: 10.3892/ol.2024.14766.

Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of treatment-naïve patients with pancreatic ductal adenocarcinoma.

Permuth J, Park M, Chen D, Basinski T, Powers B, Gwede C Front Oncol. 2024; 14:1362244.

PMID: 39109281 PMC: 11300308. DOI: 10.3389/fonc.2024.1362244.

Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.

Tan S, Zheng Q, Zhang W, Zhou M, Xia C, Feng W Front Immunol. 2024; 15():1408700.

PMID: 39050856 PMC: 11266030. DOI: 10.3389/fimmu.2024.1408700.

References

Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M . The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One. 2018; 13(2):e0193018. PMC: 5814002. DOI: 10.1371/journal.pone.0193018. View

Min K, Kwon M, Kim D, Son B, Kim E, Oh Y . Persistent elevation of postoperative neutrophil-to-lymphocyte ratio: A better predictor of survival in gastric cancer than elevated preoperative neutrophil-to-lymphocyte ratio. Sci Rep. 2017; 7(1):13967. PMC: 5656603. DOI: 10.1038/s41598-017-13969-x. View

Takahashi M . [Genetic Mutation Accumulation and Clinical Outcome of Immune Checkpoint Blockade Therapy]. Gan To Kagaku Ryoho. 2016; 43(6):678-82. View

Kang Y, Boku N, Satoh T, Ryu M, Chao Y, Kato K . Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10111):2461-2471. DOI: 10.1016/S0140-6736(17)31827-5. View

Tanaka H, Muguruma K, Toyokawa T, Kubo N, Ohira M, Hirakawa K . Differential impact of the neutrophil-lymphocyte ratio on the survival of patients with stage IV gastric cancer. Dig Surg. 2014; 31(4-5):327-33. DOI: 10.1159/000369278. View

Wang L, Zhang Q, Ni S, Tan C, Cai X, Huang D . Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. Cancer Med. 2018; 7(6):2612-2620. PMC: 6010739. DOI: 10.1002/cam4.1502. View

Pereira M, Ramos M, Faraj S, Dias A, Yagi O, Zilberstein B . Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. J Surg Oncol. 2018; 117(5):829-839. DOI: 10.1002/jso.25022. View

Musri F, Mutlu H, Karakurt Eryilmaz M, Kivrak Salim D, Gunduz S, Coskun H . The Neutrophil to Lymphocyte Ratio is an Independent Prognostic Factor in Patients with Metastatic Gastric Cancer. Asian Pac J Cancer Prev. 2016; 17(3):1309-12. DOI: 10.7314/apjcp.2016.17.3.1309. View

Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F . Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer. 2016; 20(5):825-833. DOI: 10.1007/s10120-016-0681-6. View

10.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W . Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017; 111:176-181. DOI: 10.1016/j.lungcan.2017.07.024. View

11.

Akbay E, Koyama S, Liu Y, Dries R, Bufe L, Silkes M . Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. J Thorac Oncol. 2017; 12(8):1268-1279. PMC: 5532066. DOI: 10.1016/j.jtho.2017.04.017. View

12.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz L, Mandrekar S . iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017; 18(3):e143-e152. PMC: 5648544. DOI: 10.1016/S1470-2045(17)30074-8. View

13.

Ogata T, Satake H, Ogata M, Hatachi Y, Yasui H . Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report. Case Rep Oncol. 2018; 11(1):143-150. PMC: 5903152. DOI: 10.1159/000487477. View

14.

Guthrie G, Charles K, Roxburgh C, Horgan P, McMillan D, Clarke S . The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013; 88(1):218-30. DOI: 10.1016/j.critrevonc.2013.03.010. View

15.

Gonda K, Shibata M, Sato Y, Washio M, Takeshita H, Shigeta H . Elevated neutrophil-to-lymphocyte ratio is associated with nutritional impairment, immune suppression, resistance to S-1 plus cisplatin, and poor prognosis in patients with stage IV gastric cancer. Mol Clin Oncol. 2017; 7(6):1073-1078. PMC: 5740823. DOI: 10.3892/mco.2017.1438. View

16.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

17.

Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y . Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2012; 58(1):58-64. DOI: 10.1016/j.jhep.2012.08.017. View

18.

Alexandrov L, Nik-Zainal S, Wedge D, Aparicio S, Behjati S, Biankin A . Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-21. PMC: 3776390. DOI: 10.1038/nature12477. View

19.

Jung M, Ryu M, Oh D, Kang M, Zang D, Hwang I . Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer. 2018; 21(5):819-830. DOI: 10.1007/s10120-018-0806-1. View

20.

Templeton A, McNamara M, Seruga B, Vera-Badillo F, Aneja P, Ocana A . Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6):dju124. DOI: 10.1093/jnci/dju124. View